Last 12 months
Inside the activity.
0 purchase rows · 35 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 2 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 16 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 17 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 04, 2018 Filed May 8, 2018 21:33 UTC |
Watson AshleySVP Chief Ethics & Com Officer
|
GrantStock Option (right to buy) · Derivative | 18,298 | $0.00 Strike: $57.75 | $0.00 |
DisclosureSEC source: 0001225208-18-008941 · doc4.xml · derivative · entry 4 Watson Ashley · CIK 0001708109 · SVP Chief Ethics & Com Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,298 Underlying: Common Stock · 18,298 shares Expires 2028-05-03 F5 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/4/2019, 5/4/2020 and 5/4/2021. Read SEC document |
| May 04, 2018 Filed May 8, 2018 21:33 UTC |
Watson AshleySVP Chief Ethics & Com Officer
|
GrantRestricted Stock Unit · Derivative | 2,597 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-008941 · doc4.xml · derivative · entry 3 Watson Ashley · CIK 0001708109 · SVP Chief Ethics & Com Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,597 Underlying: Common Stock · 2,597 shares Expires 2021-05-04 F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F4 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/4/2019, 5/4/2020 and 5/4/2021. Read SEC document |
| May 04, 2018 Filed May 8, 2018 21:33 UTC |
Zachary JenniferEVP, General Counsel
|
GrantStock Option (right to buy) · Derivative | 73,191 | $0.00 Strike: $57.75 | $0.00 |
DisclosureSEC source: 0001225208-18-008942 · doc4.xml · derivative · entry 2 Zachary Jennifer · CIK 0001737231 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,191 Underlying: Common Stock · 73,191 shares Expires 2028-05-03 F3 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/4/2019, 5/4/2020 and 5/4/2021. Read SEC document |
| May 04, 2018 Filed May 8, 2018 21:33 UTC |
Zachary JenniferEVP, General Counsel
|
GrantRestricted Stock Unit · Derivative | 17,316 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-008942 · doc4.xml · derivative · entry 1 Zachary Jennifer · CIK 0001737231 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,316 Underlying: Common Stock · 17,316 shares Expires 2021-05-04 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F2 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/4/2019, 5/4/2020 and 5/4/2021. Read SEC document |
| May 01, 2018 Filed May 2, 2018 16:18 UTC |
Chattopadhyay SanatExe V-P & Pres. MMD
|
Exercise / conversionRestricted Stock Unit · Derivative | 4,009 | $58.87 | $236,009.83 |
DisclosureSEC source: 0001225208-18-008420 · doc4.xml · derivative · entry 3 Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,009 shares Expires 2018-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
| May 01, 2018 Filed May 2, 2018 16:18 UTC |
Chattopadhyay SanatExe V-P & Pres. MMD
|
Tax withholdingCommon Stock | 1,142 | $58.87 | $67,229.54 |
DisclosureSEC source: 0001225208-18-008420 · doc4.xml · nonDerivative · entry 2 Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,467.08 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 01, 2018 Filed May 2, 2018 16:18 UTC |
Chattopadhyay SanatExe V-P & Pres. MMD
|
Exercise / conversionCommon Stock | 4,009 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-008420 · doc4.xml · nonDerivative · entry 1 Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,609.08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2018 Filed May 2, 2018 16:18 UTC |
Karachun Rita ASr. VP Fince-Global Controller
|
Exercise / conversionRestricted Stock Unit · Derivative | 3,007 | $58.87 | $177,022.09 |
DisclosureSEC source: 0001225208-18-008421 · doc4.xml · derivative · entry 3 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,007 shares Expires 2018-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
| May 01, 2018 Filed May 2, 2018 16:18 UTC |
Karachun Rita ASr. VP Fince-Global Controller
|
Tax withholdingCommon Stock | 1,030 | $58.87 | $60,636.10 |
DisclosureSEC source: 0001225208-18-008421 · doc4.xml · nonDerivative · entry 2 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,174.972 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 01, 2018 Filed May 2, 2018 16:18 UTC |
Karachun Rita ASr. VP Fince-Global Controller
|
Exercise / conversionCommon Stock | 3,007 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-008421 · doc4.xml · nonDerivative · entry 1 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,204.972 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2018 Filed May 2, 2018 16:19 UTC |
Watson AshleySVP Chief Ethics & Com Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 10,441 | $58.87 | $614,661.67 |
DisclosureSEC source: 0001225208-18-008422 · doc4.xml · derivative · entry 4 Watson Ashley · CIK 0001708109 · SVP Chief Ethics & Com Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,441 shares Expires 2018-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
| May 01, 2018 Filed May 2, 2018 16:19 UTC |
Watson AshleySVP Chief Ethics & Com Officer
|
Tax withholdingCommon Stock | 3,151 | $58.87 | $185,499.37 |
DisclosureSEC source: 0001225208-18-008422 · doc4.xml · nonDerivative · entry 2 Watson Ashley · CIK 0001708109 · SVP Chief Ethics & Com Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,631.721 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 01, 2018 Filed May 2, 2018 16:19 UTC |
Watson AshleySVP Chief Ethics & Com Officer
|
Exercise / conversionCommon Stock | 10,441 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-008422 · doc4.xml · nonDerivative · entry 1 Watson Ashley · CIK 0001708109 · SVP Chief Ethics & Com Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,782.721 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 16, 2018 Filed Apr 17, 2018 21:56 UTC |
GRADDICK WEIR MIRIAN MExe V-P, HR
|
SaleCommon Stock | 24,000 | $58.00 | $1,392,000.00 |
DisclosureSEC source: 0001225208-18-007833 · doc4.xml · nonDerivative · entry 1 GRADDICK WEIR MIRIAN M · CIK 0001168014 · Exe V-P, HR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,433.319 F1 · kind: The sale reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| April 02, 2018 Filed Apr 3, 2018 22:08 UTC |
GLOCER THOMAS HDirector
|
GrantPhantom Stock · Derivative | 633.5649 | $53.27 | $33,750.00 |
DisclosureSEC source: 0001225208-18-007253 · doc4.xml · derivative · entry 2 GLOCER THOMAS H · CIK 0001140799 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,262.1799 Underlying: Common Stock · 633.5649 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| April 02, 2018 Filed Apr 3, 2018 22:08 UTC |
LAZARUS ROCHELLE BDirector
|
GrantPhantom Stock · Derivative | 539.7034 | $53.27 | $28,750.00 |
DisclosureSEC source: 0001225208-18-007254 · doc4.xml · derivative · entry 3 LAZARUS ROCHELLE B · CIK 0001082206 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,495.1904 Underlying: Common Stock · 539.7034 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| April 02, 2018 Filed Apr 3, 2018 22:08 UTC |
Noseworthy John HDirector
|
GrantPhantom Stock · Derivative | 539.7034 | $53.27 | $28,750.00 |
DisclosureSEC source: 0001225208-18-007255 · doc4.xml · derivative · entry 2 Noseworthy John H · CIK 0001706596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,286.7514 Underlying: Common Stock · 539.7034 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| April 02, 2018 Filed Apr 3, 2018 22:08 UTC |
THULIN INGE GDirector
|
GrantPhantom Stock · Derivative | 179.9011 | $53.27 | $9,583.33 |
DisclosureSEC source: 0001225208-18-007256 · doc4.xml · derivative · entry 2 THULIN INGE G · CIK 0001263739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 443.7125 Underlying: Common Stock · 179.9011 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. Read SEC document |
| April 02, 2018 Filed Apr 3, 2018 22:08 UTC |
WEEKS WENDELL PDirector
|
GrantPhantom Stock · Derivative | 539.7034 | $53.27 | $28,750.00 |
DisclosureSEC source: 0001225208-18-007257 · doc4.xml · derivative · entry 2 WEEKS WENDELL P · CIK 0001206158 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,112.7634 Underlying: Common Stock · 539.7034 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| April 02, 2018 Filed Apr 3, 2018 22:09 UTC |
Wendell Peter CDirector
|
GrantPhantom Stock · Derivative | 539.7034 | $53.27 | $28,750.00 |
DisclosureSEC source: 0001225208-18-007258 · doc4.xml · derivative · entry 2 WENDELL PETER C · CIK 0001032635 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,134.0974 Underlying: Common Stock · 539.7034 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:46 UTC |
THULIN INGE GDirector
|
GrantPhantom Stock · Derivative | 263.8114 | $53.70 | $14,166.67 |
DisclosureSEC source: 0001225208-18-005284 · doc4.xml · derivative · entry 2 THULIN INGE G · CIK 0001263739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263.8114 Underlying: Common Stock · 263.8114 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. Read SEC document |
| February 27, 2018 Filed Mar 2, 2018 00:32 UTC |
Schechter Adam HEVP & Pres-Global Human Health
|
GrantCommon Stock | 34,094 | $54.72 | $1,865,623.68 |
DisclosureSEC source: 0001225208-18-005009 · doc4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,094 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/15. Performance shares were paid out at 138 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2017. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 27, 2018 Filed Mar 2, 2018 00:32 UTC |
FRAZIER KENNETH CDirector · Chairman, President & CEO
|
GrantCommon Stock | 110,393 | $54.72 | $6,040,704.96 |
DisclosureSEC source: 0001225208-18-005010 · doc4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 710,697.063 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/15. Performance shares were paid out at 138 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2017. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 27, 2018 Filed Mar 2, 2018 00:32 UTC |
PERLMUTTER ROGER MExe V-P & Pres, MRL
|
GrantCommon Stock | 34,931 | $54.72 | $1,911,424.32 |
DisclosureSEC source: 0001225208-18-005011 · doc4.xml · nonDerivative · entry 1 PERLMUTTER ROGER M · CIK 0001184228 · Exe V-P & Pres, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,906.628 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/15. Performance shares were paid out at 138 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2017. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 27, 2018 Filed Mar 2, 2018 00:32 UTC |
Watson AshleySVP Chief Ethics & Com Officer
|
GrantCommon Stock | 2,322 | $54.72 | $127,059.84 |
DisclosureSEC source: 0001225208-18-005012 · doc4.xml · nonDerivative · entry 1 Watson Ashley · CIK 0001708109 · SVP Chief Ethics & Com Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,322 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/15. Performance shares were paid out at 138 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2017. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 27, 2018 Filed Mar 2, 2018 00:32 UTC |
GRADDICK WEIR MIRIAN MExe V-P, HR
|
GrantCommon Stock | 13,949 | $54.72 | $763,289.28 |
DisclosureSEC source: 0001225208-18-005013 · doc4.xml · nonDerivative · entry 1 GRADDICK WEIR MIRIAN M · CIK 0001168014 · Exe V-P, HR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,433.319 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/15. Performance shares were paid out at 138 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2017. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 27, 2018 Filed Mar 2, 2018 00:33 UTC |
Chattopadhyay SanatExe V-P & Pres. MMD
|
GrantCommon Stock | 4,522 | $54.72 | $247,443.84 |
DisclosureSEC source: 0001225208-18-005014 · doc4.xml · nonDerivative · entry 1 Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,181.926 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/15. Performance shares were paid out at 138 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2017. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 27, 2018 Filed Mar 2, 2018 00:33 UTC |
Gerberding Julie L.EVP Strat Comm, Gl Pub Policy
|
GrantCommon Stock | 9,062 | $54.72 | $495,872.64 |
DisclosureSEC source: 0001225208-18-005015 · doc4.xml · nonDerivative · entry 1 Gerberding Julie L. · CIK 0001628884 · EVP Strat Comm, Gl Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,276.846 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/15. Performance shares were paid out at 138 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2017. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 27, 2018 Filed Mar 2, 2018 00:33 UTC |
DeLuca Richard R.EVP&Pres, Merck Animal Health
|
GrantCommon Stock | 12,575 | $54.72 | $688,104.00 |
DisclosureSEC source: 0001225208-18-005016 · doc4.xml · nonDerivative · entry 1 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,380.841 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/15. Performance shares were paid out at 138 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2017. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 27, 2018 Filed Mar 2, 2018 00:33 UTC |
Holston Michael JEVP, General Counsel
|
GrantCommon Stock | 20,694 | $54.72 | $1,132,375.68 |
DisclosureSEC source: 0001225208-18-005017 · doc4.xml · nonDerivative · entry 1 Holston Michael J · CIK 0001390613 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,786.227 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/15. Performance shares were paid out at 138 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2017. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 27, 2018 Filed Mar 2, 2018 00:33 UTC |
Davis Robert MEVP, Global Svcs & CFO
|
GrantCommon Stock | 30,908 | $54.72 | $1,691,285.76 |
DisclosureSEC source: 0001225208-18-005018 · doc4.xml · nonDerivative · entry 1 Davis Robert M · CIK 0001363076 · EVP, Global Svcs & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,128.164 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/15. Performance shares were paid out at 138 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2017. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 27, 2018 Filed Mar 2, 2018 00:33 UTC |
Karachun Rita ASr. VP Fince-Global Controller
|
GrantCommon Stock | 3,090 | $54.72 | $169,084.80 |
DisclosureSEC source: 0001225208-18-005019 · doc4.xml · nonDerivative · entry 1 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,197.972 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/15. Performance shares were paid out at 138 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2017. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 09, 2018 Filed Feb 9, 2018 21:48 UTC |
DeLuca Richard R.EVP&Pres, Merck Animal Health
|
Exercise / conversionRestricted Stock Unit · Derivative | 8,572 | $54.73 | $469,145.56 |
DisclosureSEC source: 0001225208-18-002429 · doc4.xml · derivative · entry 4 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,572 shares Expires 2018-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
| February 09, 2018 Filed Feb 9, 2018 21:48 UTC |
DeLuca Richard R.EVP&Pres, Merck Animal Health
|
Tax withholdingCommon Stock | 2,974 | $54.73 | $162,767.02 |
DisclosureSEC source: 0001225208-18-002429 · doc4.xml · nonDerivative · entry 2 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,805.841 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 09, 2018 Filed Feb 9, 2018 21:48 UTC |
DeLuca Richard R.EVP&Pres, Merck Animal Health
|
Exercise / conversionCommon Stock | 8,572 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-002429 · doc4.xml · nonDerivative · entry 1 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,779.841 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2018 Filed Feb 9, 2018 21:48 UTC |
WEEKS WENDELL PDirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $38.04 | $0.00 |
DisclosureSEC source: 0001225208-18-002430 · doc4.xml · derivative · entry 3 WEEKS WENDELL P · CIK 0001206158 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2018-04-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option became exercisable in equal installments on 4/30/2009, 4/30/2010 and 4/30/2011. Read SEC document |
| February 09, 2018 Filed Feb 9, 2018 21:48 UTC |
WEEKS WENDELL PDirector
|
SaleCommon Stock | 5,000 | $53.57 | $267,833.00 |
DisclosureSEC source: 0001225208-18-002430 · doc4.xml · nonDerivative · entry 2 WEEKS WENDELL P · CIK 0001206158 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 Read SEC document |
| February 09, 2018 Filed Feb 9, 2018 21:48 UTC |
WEEKS WENDELL PDirector
|
Exercise / conversionCommon Stock | 5,000 | $38.04 | $190,200.00 |
DisclosureSEC source: 0001225208-18-002430 · doc4.xml · nonDerivative · entry 1 WEEKS WENDELL P · CIK 0001206158 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 16, 2018 Filed Jan 16, 2018 22:12 UTC |
GRADDICK WEIR MIRIAN MExe V-P, HR
|
Exercise / conversionStock Option (right to buy) · Derivative | 52,000 | $0.00 Strike: $44.30 | $0.00 |
DisclosureSEC source: 0001225208-18-001052 · doc4.xml · derivative · entry 5 GRADDICK WEIR MIRIAN M · CIK 0001168014 · Exe V-P, HR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 52,000 shares Expires 2018-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option became exercisable in equal installments on 2/28/2009, 2/28/2010 and 2/28/2011. Read SEC document |
| January 16, 2018 Filed Jan 16, 2018 22:12 UTC |
GRADDICK WEIR MIRIAN MExe V-P, HR
|
SaleCommon Stock | 52,000 | $61.63 | $3,204,760.00 |
DisclosureSEC source: 0001225208-18-001052 · doc4.xml · nonDerivative · entry 4 GRADDICK WEIR MIRIAN M · CIK 0001168014 · Exe V-P, HR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,484.319 F2 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| January 16, 2018 Filed Jan 16, 2018 22:12 UTC |
GRADDICK WEIR MIRIAN MExe V-P, HR
|
SaleCommon Stock | 8,000 | $61.63 | $493,040.00 |
DisclosureSEC source: 0001225208-18-001052 · doc4.xml · nonDerivative · entry 3 GRADDICK WEIR MIRIAN M · CIK 0001168014 · Exe V-P, HR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,484.319 F1 · kind: The sale reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| January 16, 2018 Filed Jan 16, 2018 22:12 UTC |
GRADDICK WEIR MIRIAN MExe V-P, HR
|
Exercise / conversionCommon Stock | 52,000 | $44.30 | $2,303,600.00 |
DisclosureSEC source: 0001225208-18-001052 · doc4.xml · nonDerivative · entry 2 GRADDICK WEIR MIRIAN M · CIK 0001168014 · Exe V-P, HR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,484.319 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 16, 2018 Filed Jan 16, 2018 22:13 UTC |
Holston Michael JEVP, General Counsel
|
SaleCommon Stock | 12,500 | $61.63 | $770,375.00 |
DisclosureSEC source: 0001225208-18-001053 · doc4.xml · nonDerivative · entry 1 Holston Michael J · CIK 0001390613 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,092.227 F1 · kind: The sale reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| January 16, 2018 Filed Jan 16, 2018 22:13 UTC |
Schechter Adam HEVP & Pres-Global Human Health
|
Exercise / conversionStock Option (right to buy) · Derivative | 50,994 | $0.00 Strike: $36.56 | $0.00 |
DisclosureSEC source: 0001225208-18-001054 · doc4.xml · derivative · entry 4 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 50,994 shares Expires 2021-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option became exercisable in equal installments on 5/4/2012, 5/4/2013 and 5/4/2014. Read SEC document |
| January 16, 2018 Filed Jan 16, 2018 22:13 UTC |
Schechter Adam HEVP & Pres-Global Human Health
|
SaleCommon Stock | 50,608 | $61.63 | $3,118,971.04 |
DisclosureSEC source: 0001225208-18-001054 · doc4.xml · nonDerivative · entry 3 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 62,765.9747 F2 · kind: The sale reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| January 16, 2018 Filed Jan 16, 2018 22:13 UTC |
Schechter Adam HEVP & Pres-Global Human Health
|
SaleCommon Stock | 50,994 | $61.63 | $3,142,760.22 |
DisclosureSEC source: 0001225208-18-001054 · doc4.xml · nonDerivative · entry 2 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| January 16, 2018 Filed Jan 16, 2018 22:13 UTC |
Schechter Adam HEVP & Pres-Global Human Health
|
Exercise / conversionCommon Stock | 50,994 | $36.56 | $1,864,340.64 |
DisclosureSEC source: 0001225208-18-001054 · doc4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,994 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 16, 2018 Filed Jan 19, 2018 22:30 UTC Amendment |
GRADDICK WEIR MIRIAN MExe V-P, HR
|
SaleCommon Stock | 52,000 | $61.63 | $3,204,760.00 |
DisclosureSEC source: 0001225208-18-001321 · doc4a.xml · nonDerivative · entry 4 GRADDICK WEIR MIRIAN M · CIK 0001168014 · Exe V-P, HR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,484.319 F3 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · balance_after: The original Form 4, filed on January 16, 2018, is being amended by this Form 4 amendment solely to correct an administrative error, which misreported a sale that occurred on January 12, 2018 as a total of 5,000 shares sold when in fact 8,000 shares of the Issuer's common stock were sold. As a result of this administrative error, the number of shares beneficially owned by the reporting person following the corrected transaction reflects a reduction in the number of shares reported as beneficially owned by the reporting person by 3,000 shares, and includes shares acquired in dividend reinvestment transactions. Read SEC document |
| January 16, 2018 Filed Jan 19, 2018 22:30 UTC Amendment |
GRADDICK WEIR MIRIAN MExe V-P, HR
|
SaleCommon Stock | 8,000 | $61.63 | $493,040.00 |
DisclosureSEC source: 0001225208-18-001321 · doc4a.xml · nonDerivative · entry 3 GRADDICK WEIR MIRIAN M · CIK 0001168014 · Exe V-P, HR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,484.319 F1 · kind: The sale reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan. F2 · balance_after: The original Form 4, filed on January 16, 2018, is being amended by this Form 4 amendment solely to correct an administrative error, which misreported a sale that occurred on January 12, 2018 as a total of 5,000 shares sold when in fact 8,000 shares of the Issuer's common stock were sold. As a result of this administrative error, the number of shares beneficially owned by the reporting person following the corrected transaction reflects a reduction in the number of shares reported as beneficially owned by the reporting person by 3,000 shares, and includes shares acquired in dividend reinvestment transactions. Read SEC document |
| January 16, 2018 Filed Jan 19, 2018 22:30 UTC Amendment |
GRADDICK WEIR MIRIAN MExe V-P, HR
|
Exercise / conversionCommon Stock | 52,000 | $44.30 | $2,303,600.00 |
DisclosureSEC source: 0001225208-18-001321 · doc4a.xml · nonDerivative · entry 2 GRADDICK WEIR MIRIAN M · CIK 0001168014 · Exe V-P, HR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,484.319 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · balance_after: The original Form 4, filed on January 16, 2018, is being amended by this Form 4 amendment solely to correct an administrative error, which misreported a sale that occurred on January 12, 2018 as a total of 5,000 shares sold when in fact 8,000 shares of the Issuer's common stock were sold. As a result of this administrative error, the number of shares beneficially owned by the reporting person following the corrected transaction reflects a reduction in the number of shares reported as beneficially owned by the reporting person by 3,000 shares, and includes shares acquired in dividend reinvestment transactions. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.